Expanded indication provides patients with knee osteoarthritis with the benefits of Embosphere’s consistent, predictable, and effective clinical results
Novocure (Nasdaq:NVCR) announced today that it received regulatory approval in Japan for its Optune Lua wearable device.
Pulnovo Medical announced today that it received two FDA investigational device exemption (IDE) approvals for its technology.
Breakthrough approval supports home-based testing and strengthens access to care
NAPLES, Fla., Sept. 10, 2025 /PRNewswire/ — Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial, and 50 mg per vial, Single-Dose Vials.
The trial will evaluate the effectiveness of the nsPFA cardiac surgical system during concurrent surgical procedures.
Neurescue’s device is claimed to be the first catheter to have received a CE mark for addressing non-shockable cardiac arrest.
The company has completed registration and certification for its total disc replacement products, which are now CE-marked.
Johnson & Johnson (NYSE:JNJ) announced today that the FDA approved Inlexzo, its gemcitabine intravesical drug delivery system.
Neurescue announced today that it received CE mark approval for its device designed to treat non-shockable cardiac arrest.